Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary aim: To evaluate the feasibility, usability and safety of the investigational device in clinical practice over 6 months in 50 patients.
Secondary aims: To describe the number of healthcare contacts and the adequacy of those contacts.
Study design: Traditional feasibility clinical investigationPilot feasibility open observational study.
Subjects: 50 subjects being investigated for or with a diagnosis of COPD with at least one exacerbation within the last year will be invited to voluntarily participate. Exclusion criteria is severe disease from either COPD or any severe concomitant conditions that would make home spirometry unsafe for the patient. Patients with no access to use BankID or similar electronic personal identification service and not using Android (version 8+) or iOS (version 16+) smartphones will be excluded.
Intervention: At inclusion patients will be on-boarded on to the digital platform and recommended to follow instructions in the app. The intervention is the COPD Treatment check, which is a medical device that is connected to a spirometer. Patients will be instructed to self-test on a daily basis.
Control group: There will be no control group.
Primary endpoints:
• Feasability and usability of the system in a clinical setting as determined by usage and questionnaire evaluation. Feasibility measured by proportion of participants who complete the study, compliance and adoption (system usage), time needed to train users
Secondary endpoints:
Safety of the device
- Experienced usability and the number of adverse events
Adequacy of the participant's healthcare contacts.
Patient "education" often takes the form of providers giving didactic Information and assumes that knowledge will lead to behavioural change. Although important, it may not be sufficient for promoting self-management skills. Enhancing patient knowledge is an important step towards behaviour change using self-management interventions and should include topics such as smoking cessation, correct use of inhaler devices, early recognition of exacerbations, decision-making and acting at the right time, and when to seek help. Personalized education and training that takes into account specific issues relating to the individual patient, and that aims to enhance long-term functionality and appropriate health behaviours are likely to benefit patients more. A good COPD self-management intervention is structured but personalized, with goals of motivating, engaging and supporting the patients to positively adapt their health behaviour(s) and develop skills to better manage their disease. The aim is to elicit patient motivation, confidence and competence. Systematic reviews have provided evidence that self-management interventions improve outcomes in COPD. A 2022 Cochrane review reported that interventions for people with COPD are associated with improvements in health-related quality of life (HRQoL), a lower probability of respiratory-related hospital admissions, and no excess respiratory-related and all-cause mortality risks.
One of the most important goals for treatment of COPD exacerbations are to minimize the negative impact of an exacerbation and to prevent subsequent events. Also, it is now recognized that many exacerbations are not reported to healthcare professionals for therapy and yet these events have a significant impact on health status. Thus, one focus is for COPD patients to receive education about the importance of understanding exacerbation symptoms and when to seek professional healthcare.
According to the Swedish National Board of Health and Welfare a written self-management plan should be established together with the healthcare team and be reevaluated at follow-up visits. The plan should contain information on how to adjust treatment according to for example symptoms and infections, and when it is important for the patient to contact healthcare for assistance.
The investigational device is a separate module, COPD Treatment check, embedded in the cloud-based CE-marked system called AsthmaTuner. Our hypothesis is that this digital tool will improve self-management of COPD. Thus, the aim of this study is to assess the feasibility, usability and safety of the COPD Treatment check in clinical practice. Secondary aim is to evaluate the number of healthcare contacts and the adequacy of those contacts.
At baseline, a trained nurse will onboard and instruct patients in device handling (standard education). According to a flow algorithm, the app will instruct patients to contact their healthcare provider. The healthcare provider will be able to see collected data that is displayed in the back-end system but will not be instructed to actively monitor patients.
Data on feasibility, safety and experienced usability of the investigational device will be presented. The analysis of feasibility and the experienced benefit of using the COPD Treatment check in clinical practice is estimated on a Likert scale from 1 (strongly disagree) to 5 (strongly agree), and presented as mean and median scores. The number of clinic contacts will be presented in relation to the number of times that the app has recommended such contacts. A medical doctor will categorize the contacts as correct or incorrect, without knowing whether the contacts were initiated via the app or the patient themselves to avoid bias.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COPD treatment check | Experimental | At inclusion patients will be onboarded to the digital platform and recommended to follow instructions in the app. The intervention is the COPD Treatment check, which is a medical device that is connected to a spirometer. Patients will be instructed to self-test on a daily basis. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| COPD treatment check | Device | The investigational device is designed to support self-management of COPD. It provided patients with remote individualized feedback and recommendations for symptom relief and exacerbation management based on actual lung function and symptom report. |
| Measure | Description | Time Frame |
|---|---|---|
| The rate of participants that perceives the device feasible to use. | Feasability of the system in a clinical setting as determined by usage and questionnaire evaluation. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Adequacy of the participant's healthcare contacts and adverse events. | Number of actual clinic contacts in relation to the number of recommendations by the COPD treatment check to seek medical attention. Adverse events listed in agreement with the Clinical Investigation Plan version 5. | 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Henrik Ljungberg | Contact | +46706628642 | henrik.ljungberg@ki.se |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| KPE Lung and Allergy, QB:84, Karolinska University Hospital. | Recruiting | Solna | Stockholm County | 17164 | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34836506 | Background | Breckner A, Roth C, Glassen K, Wensing M. Self-management perspectives of elderly patients with multimorbidity and practitioners - status, challenges and further support needed? BMC Fam Pract. 2021 Nov 26;22(1):238. doi: 10.1186/s12875-021-01584-9. | |
| 11505938 | Background | Human D, Crawley F, IJesselmuiden C. Revised declaration of Helsinki. WMA will continue to revise policy as medicine and research changes. BMJ. 2001 Aug 4;323(7307):283-4. No abstract available. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
At inclusion patients will be onboarded to the digital platform and recommended to follow instructions in the app. The intervention is the COPD Treatment check, which is a medical device that is connected to a spirometer. Patients will be instructed to self-test on a daily basis. Decreasing lung function or increased symptoms will lead to a recommendation to contact healthcare.
Not provided
Not provided
Not provided
Not provided
|
| 24982491 | Background | Williams V, Price J, Hardinge M, Tarassenko L, Farmer A. Using a mobile health application to support self-management in COPD: a qualitative study. Br J Gen Pract. 2014 Jul;64(624):e392-400. doi: 10.3399/bjgp14X680473. |
| 22789911 | Background | Chau JP, Lee DT, Yu DS, Chow AY, Yu WC, Chair SY, Lai AS, Chick YL. A feasibility study to investigate the acceptability and potential effectiveness of a telecare service for older people with chronic obstructive pulmonary disease. Int J Med Inform. 2012 Oct;81(10):674-82. doi: 10.1016/j.ijmedinf.2012.06.003. Epub 2012 Jul 11. |
| 22743675 | Background | Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27. |
| 16055882 | Background | Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available. |
| 35433019 | Background | Schoultz K, Svensson A, Emilsson M. Nurses' experiences of using AsthmaTuner - an eHealth self-management system for healthcare of patients with asthma. Digit Health. 2022 Apr 11;8:20552076221092542. doi: 10.1177/20552076221092542. eCollection 2022 Jan-Dec. |
| 31481605 | Background | Ljungberg H, Carleborg A, Gerber H, Ofverstrom C, Wolodarski J, Menshi F, Engdahl M, Eduards M, Nordlund B. Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial. Eur Respir J. 2019 Nov 14;54(5):1900983. doi: 10.1183/13993003.00983-2019. Print 2019 Nov. |
| Background | Regions, S.A.o.L.A.a., Treatment plan COPD. https://registercentrum.blob.core.windows.net/lvr/r/KOL-Min-behandlingsplan-S1g1JxirfL.pdf, 2024 Dec. |
| Background | Welfare, S.N.B.o.H.a., Performance assessment of asthma and COPD healthcare. https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-riktlinjer/2018-12-44-eng.pdf, 2018. |
| 14990395 | Background | Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004 Jun 15;169(12):1298-303. doi: 10.1164/rccm.200310-1443OC. Epub 2004 Feb 27. |
| 35001366 | Background | Schrijver J, Lenferink A, Brusse-Keizer M, Zwerink M, van der Valk PD, van der Palen J, Effing TW. Self-management interventions for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4. |
| 27076595 | Background | Effing TW, Vercoulen JH, Bourbeau J, Trappenburg J, Lenferink A, Cafarella P, Coultas D, Meek P, van der Valk P, Bischoff EW, Bucknall C, Dewan NA, Early F, Fan V, Frith P, Janssen DJ, Mitchell K, Morgan M, Nici L, Patel I, Walters H, Rice KL, Singh S, Zuwallack R, Benzo R, Goldstein R, Partridge MR, van der Palen J. Definition of a COPD self-management intervention: International Expert Group consensus. Eur Respir J. 2016 Jul;48(1):46-54. doi: 10.1183/13993003.00025-2016. Epub 2016 Apr 13. |
| 30806700 | Background | Riley CM, Sciurba FC. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA. 2019 Feb 26;321(8):786-797. doi: 10.1001/jama.2019.0131. |
| 35095272 | Background | Cravo A, Attar D, Freeman D, Holmes S, Ip L, Singh SJ. The Importance of Self-Management in the Context of Personalized Care in COPD. Int J Chron Obstruct Pulmon Dis. 2022 Jan 22;17:231-243. doi: 10.2147/COPD.S343108. eCollection 2022. |
| Background | Organization, W.H., WHO package of essential non-communicable diseases interventions for primary health care. https://iris.who.int/bitstream/handle/10665/334186/9789240009226-eng.pdf?sequence=1. |
| 23791463 | Background | Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, Macnee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013 Sep;107(9):1376-84. doi: 10.1016/j.rmed.2013.05.001. Epub 2013 Jun 19. |
| 16135722 | Background | Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J. 2005 Sep;26(3):420-8. doi: 10.1183/09031936.05.00136304. |
| 33011203 | Background | Zafari Z, Li S, Eakin MN, Bellanger M, Reed RM. Projecting Long-term Health and Economic Burden of COPD in the United States. Chest. 2021 Apr;159(4):1400-1410. doi: 10.1016/j.chest.2020.09.255. Epub 2020 Oct 2. |
| 31273036 | Background | Halpin DMG, Celli BR, Criner GJ, Frith P, Lopez Varela MV, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, Aisanov Z, Obaseki D, Decker R, Agusti A. It is time for the world to take COPD seriously: a statement from the GOLD board of directors. Eur Respir J. 2019 Jul 4;54(1):1900914. doi: 10.1183/13993003.00914-2019. Print 2019 Jul. No abstract available. |
| 17132052 | Background | Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. doi: 10.1371/journal.pmed.0030442. |
| 28182564 | Background | Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, Lopez Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017 Mar 6;49(3):1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar. |
| 21595747 | Background | Nordlund B, Konradsen JR, Pedroletti C, Kull I, Hedlin G. The clinical benefit of evaluating health-related quality-of-life in children with problematic severe asthma. Acta Paediatr. 2011 Nov;100(11):1454-60. doi: 10.1111/j.1651-2227.2011.02359.x. Epub 2011 Jun 16. |
| 17689234 | Background | Jansson SA, Ronmark E, Forsberg B, Lofgren C, Lindberg A, Lundback B. The economic consequences of asthma among adults in Sweden. Respir Med. 2007 Nov;101(11):2263-70. doi: 10.1016/j.rmed.2007.06.029. Epub 2007 Aug 6. |
| 17090573 | Background | Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax. 2007 Mar;62(3):237-41. doi: 10.1136/thx.2006.068379. Epub 2006 Nov 7. |
| 17507545 | Background | Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. doi: 10.1164/rccm.200703-456SO. Epub 2007 May 16. |
| Background | World Health Organization: Chronic obstructive pulmonary disease (COPD):. [cited 2024 Dec. |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |